Skip to main content
Premium Trial:

Request an Annual Quote

Tandem Labs Acquires Linden Technologies Unit PharmaKD

NEW YORK (GenomeWeb News) — Tandem Labs, a Salt Lake City-based bioanalytical and immunoanalytical testing firm, today announced that it has acquired PharmaKD, a subsidiary of Linden Technologies.
 
Through the acquisition, Tandem gets the rights to PharmaKD’s DMDiscovery drug metabolism technology for increasing the productivity of drug metabolite identification and quantitation, and MarkerScan, a biomarker discovery and screening process for identifying potential biomarkers.
 
Under the agreement, Tandem Labs will “retain key personnel, intellectual property portfolios, proprietary informatics, scientific instruments, and 7,000 square feet of operational space from PharmaKD,” the company said.
 
PharmaKD has been renamed Tandem Labs-New England and will offer metabolite profiling, identification, and quantitation; biomarker discovery and screening; protein-binding assays; and discovery bioanalytical support services, Tandem said.
 
Financial details of the transaction were undisclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.